What is Leerink Partnrs’ Estimate for CRBU FY2025 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Stock analysts at Leerink Partnrs cut their FY2025 earnings estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.77) per share for the year, down from their prior forecast of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.83) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at $0.28 EPS.

A number of other research analysts have also recently commented on CRBU. Citigroup reduced their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock opened at $1.52 on Friday. Caribou Biosciences has a 12 month low of $1.47 and a 12 month high of $8.33. The business’s 50-day moving average price is $1.84 and its 200-day moving average price is $1.99.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million.

Institutional Investors Weigh In On Caribou Biosciences

A number of large investors have recently added to or reduced their stakes in the company. PFM Health Sciences LP raised its stake in shares of Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after purchasing an additional 536,162 shares during the period. Geode Capital Management LLC raised its position in Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. FMR LLC lifted its holdings in Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after buying an additional 109,606 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Caribou Biosciences in the 2nd quarter worth approximately $2,432,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.